| Q38082417 | 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type |
| Q44647880 | Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. |
| Q58005428 | Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis |
| Q38575581 | Diagnostic tools for post-gastric bypass hypoglycaemia |
| Q38169928 | Neuroendocrine tumours: the role of imaging for diagnosis and therapy |
| Q37273065 | Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging |
| Q38051064 | PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine |
| Q38038098 | Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors. |
| Q38036127 | Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. |
| Q59806843 | Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging |